Table 2.
Positive responses based on the secretion of IFN‐γ after Schu‐S4 stimulation measured by MSD assay
|
Time Post‐Vaccination |
Group a | |||
|---|---|---|---|---|
| DVC‐LVS | USAMRIID‐LVS | |||
| n b /N (%) | 95% CI | n/N (%) | 95% CI | |
| Day 8 | 27/100 (27.0) | 18.6, 36.8 | 30/107 (28.0) | 19.8, 37.5 |
| Day 14 | 44/99 (44.4) | 34.5, 54.8 | 39/104 (37.5) | 28.2, 47.5 |
| Day 28 | 61/99 (61.6) | 51.3, 71.2 | 65/103 (63.1) | 53.0, 72.4 |
| Day 56 | 75/99 (75.8) | 66.1, 83.8 | 69/102 (67.6) | 57.7, 76.6 |
| Day 180 | 65/89 (73.0) | 62.6, 81.9 | 65/94 (69.1) | 58.8, 78.3 |
| Any (8–180) | 92/102 (90.2) | 82.7, 95.2 | 98/108 (90.7) | 83.6, 95.5 |
a
Per‐protocol population.
b
Positive criteria: (1) Visit (SCHU‐S4 [pg mL−1]/Media [pg mL−1]) ≥ 2 and (2) Visit (SCHU‐S4 [pg mL−1]/Media [pg mL−1]) ≥ 2 × baseline (day 0) (SCHU‐S4 [pg mL−1]/Media [pg mL−1]).